Arcturus Therapeutics Holdings Inc.
ARCT
$6.65
$0.060.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -39.40% | -3.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -39.40% | -3.68% | |||
| Cost of Revenue | -88.70% | -15.23% | |||
| Gross Profit | 1,180.52% | 76.81% | |||
| SG&A Expenses | 0.58% | -8.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.67% | -13.61% | |||
| Operating Income | -42.15% | 30.96% | |||
| Income Before Tax | -46.56% | 34.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -46.49% | 34.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -46.49% | 34.78% | |||
| EBIT | -42.15% | 30.96% | |||
| EBITDA | -45.33% | 32.37% | |||
| EPS Basic | -46.16% | 34.84% | |||
| Normalized Basic EPS | -46.22% | 34.85% | |||
| EPS Diluted | -46.16% | 34.84% | |||
| Normalized Diluted EPS | -46.22% | 34.85% | |||
| Average Basic Shares Outstanding | 0.22% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.22% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||